|Day Low/High||194.01 / 198.66|
|52 Wk Low/High||141.41 / 249.27|
CAT not going down on bearish news gets us closer to a bottom and buy recommendation.
The S&P 500 fell almost 7% in the third quarter, the worst showing in four years.
OIH's path of least resistance is down. And quick follow-ups on NKE, ZTS and FCX.
Grexit woes continue to depress prices, but SCOTUS helps hospitals.
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
Moving past resistance, there's plenty of upside potential.
In 13-F filings with the Securities and Exchange Commission, Daniel Loeb's Third Point, Soros Fund Management, and other large fund managers disclosed big stakes in Chinese e-commerce giant Alibaba.
Our market's been a terrific place to invest while Europe withers.
At a London conference, these two U.S. companies get some attention.
Kindred Biosciences stock has more than doubled since it started trading in December, but the company's employees are hard at work developing its osteoarthritis drug.
Solid yielders like these should provide some much-needed cushion in the coming days.
Newly spun-off from Pfizer, Zoetis has big plans for its animal health business in the emerging markets, says the company's CEO Juan Ramon Alaix.